Combined phacoemulsification and viscocanalostomy with Ologen implant versus combined phacoemulsification and viscocanalostomy

Ahmed A M Gad, Bahaa-Eldin Hasan Abdulhalim, Ayman Lotfy, Ayman Mohamed Abdelrahman, Ahmed Samir Ahmed, Ahmed A M Gad, Bahaa-Eldin Hasan Abdulhalim, Ayman Lotfy, Ayman Mohamed Abdelrahman, Ahmed Samir Ahmed

Abstract

Background: To study the efficacy of the biodegradable collagen implant Ologen® as an adjuvant in phaco-viscocanalostomy in patients with coexisting cataract and primary open angle glaucoma.

Methods: This prospective, interventional, randomized clinical study was done at Alpha Vision Center, Zagazig, Egypt. Patients with coexisting cataract and glaucoma were randomized to receive either phaco-viscocanalostomy (Phacovisco group) (39 eyes) or phaco-viscocanalostomy with Ologen® implant (OloPhacovisco group) (40 eyes). Follow-up period was 2 years. Nd:YAG laser goniopuncture was done in cases where the intraocular pressure (IOP) was elevated above 21 mmHg after discontinuation of corticosteroid eye drops at any follow-up visit.

Results: No significant operative or postoperative complications (other than failure) were encountered in either group. At 2 years follow-up, the mean IOP level was statistically significantly decreased in the OloPhacovisco group (p = 0.02) and complete success occurred in 23 eyes (59.0%) in the Phacovisco group and in 32 eyes (80.0%) in the OloPhacovisco group. There was a statistically significant higher success rate regarding complete success in patients that received Ologen® implant (p = 0.04).

Conclusions: Ologen® implant improved the success rate of phaco-viscocanalostomy. Larger studies with longer follow-up periods may be required to confirm these findings.

Trial registration: This trial was retrospectively registered on 20/12/2018 under the number ( NCT03782051 ).

Keywords: Glaucoma; Ologen; Phacoemulsification; Viscocanalostomy.

Conflict of interest statement

Ethics approval and consent to participate

The study was approved by the Ethical Committee of Alpha Vision Center. The study adhered to the tenets of the Declaration of Helsinki. A written informed consent was obtained from every patient after explanation of the procedure and the possible consequences of the surgery.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Deep flap dissection. a Blunt dissection of deep scleral flap with microsponge to make a Descematic window. b Removal of deep flap by Vannas scissors
Fig. 2
Fig. 2
Ologen insertion. Insertion of the biodegradable Ologen® implant at the site of the removed deep scleral flap

References

    1. Johnson DH, Johnson M. How does Cillino S, Di pace F, Cillino G, Casuccio a. Biodegradable collagen matrix implant vs mitomycin-C as an adjuvant in trabeculectomy: a 24-month, randomized clinical trial. Eye (Lond) 2011;25:1598–1606. doi: 10.1038/eye.2011.63.
    1. Narayanaswamy A, Perera SA, Htoon HM, et al. Efficacy and safety of collagen matrix implants in phacotrabeculectomy and comparison with mitomycin C augmented phacotrabeculectomy at 1 year. Clin Exp Ophthalmol. 2013;41:552–560. doi: 10.1111/ceo.12058.
    1. Johnson MS, Sarkisian SR., Jr Using a collagen matrix implant (Ologen) versus mitomycin-C as a wound healing modulator in trabeculectomy with the Ex-PRESS mini glaucoma device: a 12-month retrospective review. J Glaucoma. 2014;23:649–652. doi: 10.1097/IJG.0000000000000018.
    1. Hondur A, Onol M, Hasanreisoglu B. Nonpenetrating glaucoma surgery: meta-analysis of recent results. J Glaucoma. 2008;17:139–146. doi: 10.1097/IJG.0b013e31814b98f7.
    1. Johnson DH, Johnson M. Nonpenetrating glaucoma surgery work? Aqueous outflow resistance and glaucoma surgery. J Glaucoma. 2001;10:55–67. doi: 10.1097/00061198-200102000-00011.
    1. Delarive T, Rossier A, Rossier S, et al. Aqueous dynamic and histological findings after deep sclerectomy with collagen implant in an animal model. Br J Ophthalmol. 2003;87:1340–1344. doi: 10.1136/bjo.87.11.1340.
    1. Chiou AG, Mermoud A, Underdahl JP, et al. An ultrasound biomicroscopic study of eyes after deep sclerectomy with collagen implant. Ophthalmology. 1998;105:746–750. doi: 10.1016/S0161-6420(98)94033-7.
    1. Stegmann R, Pienaar A, Miller D. Viscocanalostomy for open-angle glaucoma in black African patients. J Cataract Refract Surg. 1999;25:316–322. doi: 10.1016/S0886-3350(99)80078-9.
    1. Mendrinos E, Mermoud A, Shaarawy T. Nonpenetrating glaucoma surgery. Surv Ophthalmol. 2008;53:592–630. doi: 10.1016/j.survophthal.2008.08.023.
    1. Demailly P, Lavat P, Kretz G, Jeanteur-Lunel MN. Nonpenetrating deep sclerectomy (NPDS) with or without collagen device (CD) in primary open-angle glaucoma: middle-term retrospective study. Int Ophthalmol. 1996;20:131–140.
    1. Sanchez E, Schnyder CC, Sickenberg M, et al. Deep sclerectomy: results with and without collagen implant. Int Ophthalmol. 1996;20:157–162.
    1. Karlen ME, Sanchez E, Schnyder CC, et al. Deep sclerectomy with collagen implant: medium term results. Br J Ophthalmol. 1999;83:6–11. doi: 10.1136/bjo.83.1.6.
    1. Sourdille P, Santiago PY, Villain F, et al. Reticulated hyaluronic acid implant in nonperforating trabecular surgery. J Cataract Refract Surg. 1999;25:332–339. doi: 10.1016/S0886-3350(99)80080-7.
    1. Gunenc U, Ozturk T, Arikan G, et al. Long-term results of viscocanalostomy and phacoviscocanalostomy: a twelve-year follow-up study. Int J Ophthalmol. 2015;8:1162–1167.
    1. Shaarawy T, Nguyen C, Schnyder C, et al. Five year results of viscocanalostomy. Br J Ophthalmol. 2003;87:441–445. doi: 10.1136/bjo.87.4.441.
    1. David VP, Kutty KG, Somasundaram N, et al. Five-year results of viscocanalostomy. Eur J Ophthalmol. 2008;18:417–422. doi: 10.1177/112067210801800316.
    1. Rosentreter A, Mellein AC, Konen WW, et al. Capsule excision and Ologen implantation for revision after glaucoma drainage device surgery. Graefes Arch Clin Exp Ophthalmol. 2010;248:1319–1324. doi: 10.1007/s00417-010-1385-y.
    1. Mermoud A, Schnyder CC, Sickenberg M, et al. Comparison of deep sclerectomy with collagen implant and trabeculectomy in open-angle glaucoma. J Cataract Refract Surg. 1999;25:323–331. doi: 10.1016/S0886-3350(99)80079-0.
    1. Ambresin A, Shaarawy T, Mermoud A. Deep sclerectomy with collagen implant in one eye compared with trabeculectomy in the other eye of the same patient. J Glaucoma. 2002;11:214–220. doi: 10.1097/00061198-200206000-00009.
    1. El Sayyad F, Helal M, El-Kholify H, et al. Nonpenetrating deep sclerectomy versus trabeculectomy in bilateral primary open-angle glaucoma. Ophthalmology. 2000;107:1671–1674. doi: 10.1016/S0161-6420(00)00263-3.
    1. Dahan E, Drusedau MU. Nonpenetrating filtration surgery for glaucoma: control by surgery only. J Cataract Refract Surg. 2000;26:695–701. doi: 10.1016/S0886-3350(00)00366-7.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever